Tyligand Bioscience key facts
as of Oct 2026- Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors.
- Tyligand Bioscience is valued at approximately $222.2M as of Oct 2026 (last reported valuation).
- It has raised $110.6M; the latest was IPO in Jan 2026.
- Notable investors include Suzhou Oriza Holdings Corporation, K2VC, Tailong VC, Suzhou Yuanfeng Capital Management, VI Ventures — 14 tracked in total.
- Status: In IPO Registration.
Tyligand Bioscience's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Tyligand Bioscience: the Monday email on marks, rounds and moves
Tyligand Bioscience funding rounds
No funding rounds for Tyligand Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Tyligand Bioscience
14+Tyligand Bioscience valuation
Tyligand Bioscience's last reported valuation was $222 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Tyligand Bioscience investors
14 investors are on record for Tyligand Bioscience, including Suzhou Oriza Holdings Corporation, K2VC, Tailong VC and Suzhou Yuanfeng Capital Management.
About Tyligand Bioscience
Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. The company provides clinical-stage drug candidates and a differentiated therapeutic pipeline, enabling cancer patients and healthcare providers with novel treatment mechanisms, improved survival outcomes, and solutions for unmet clinical needs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 64
- Website
- tyligand.com.cn/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.